Synthesis of new selective-dual inhibitors of cyclin-dependent kinases

This research aims to develop novel biologically active agents inhibiting the CDK4/6 and FLT3-ITD protein complex. The agents in this investigational pipeline have high potential for the treatment of a very aggressive form of cancer, acute myeloid leukaemia (AML). The synthesis of the target substance was carried out by a seven-step reaction sequence. Six of the eight compounds prepared are novel structures that have not yet been described in the literature. The results of biological anticancer activity testing showed that the free NH group on the terminal substituent is important for selectivity and antitumor activity. These findings are important for the future structural and synthetic design of anticancer agents of this group.